The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.
A person was concerned about applying minoxidil and tretinoin in a public airport bathroom, fearing judgment from others. Most responses reassured them that no one cares, suggesting they apply it in a stall or skip a dose without worry.
MK-677 (Ibutamoren) helped reduce hair shedding and improved muscle growth for the user. The user advises caution, noting increased appetite and potential weight gain without exercise.
Hair loss may be linked to DHT, which can both suppress and increase inflammation, potentially as a defense mechanism. Treatments like Minoxidil, Finasteride, and RU58841 are discussed, but the exact cause of hair loss remains unclear.
A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.
Bald men in Mozambique are being targeted due to superstitions that their heads contain gold, leading to dangerous rituals. The conversation humorously discusses this belief and its implications.
Thicair is a product combining microneedling and subdural vitamins for hair loss, containing ingredients like Panax Ginseng Root Extract and Copper Tripeptide-1. Users are skeptical, with one calling it "quackery."
A 31-year-old man with androgenic alopecia is considering treatments like finasteride, minoxidil, and ketoconazole shampoo but is worried about finasteride's side effects. Users recommend starting with finasteride or dutasteride for DHT blocking, suggesting topical solutions to reduce side effects.
Controlling insulin levels through intermittent fasting and a low glycemic diet may improve hair quality by reducing androgens. It's important to maintain proper nutrition, including electrolytes and protein, during fasting.
A young man faces severe hair loss in his early 20s, using treatments like dutasteride and minoxidil with little success, impacting his self-esteem and relationships. He considers hair systems and therapy as potential solutions.
The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.
A user is experiencing increased hair shedding and anxiety 80 days into using 1mg Finasteride for androgenic alopecia, after previously trying Minoxidil without success. They are considering whether to add Minoxidil again or continue with Finasteride alone.
Hyperbaric Oxygen Therapy (HBOT) is discussed as a potential treatment for androgenic alopecia due to its ability to reverse hypoxia and promote angiogenesis. The conversation explores its potential benefits for hair loss, though no studies have been conducted on this application yet.
The conversation discusses using microneedling with copper peptides, specifically GHK-Cu, for hair loss treatment. Some users combine it with minoxidil and topical finasteride, applying peptides either topically or through injection.
The conversation discusses various treatments for hair loss, including minoxidil, finasteride, and topical dutasteride, with users debating their effectiveness and side effects. Despite the treatments, many believe androgenetic alopecia (AGA) ultimately prevails in the long term.
Berlin scientists are working on growing hair from adult stem cells. The conversation mentions interest in learning more about the current development of this research.
AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.
A 28-year-old male is experiencing temple regrowth but crown thinning while using 5mg minoxidil and 0.5mg dutasteride. The shedding phase is seen as a positive sign of treatment effectiveness, with expectations of noticeable improvements around 6 to 12 months.
Fibrin-based hydrogels support stem cells for hair follicle regeneration, showing promise for alopecia treatment. They enhance cell viability, maintain stemness, and induce hair growth without teratoma formation.
A person is experimenting with microneedling on one temple while using Minoxidil to address hair loss. They plan to needle weekly and apply Minoxidil twice daily, avoiding application around needling sessions.
A woman with androgenetic alopecia uses Dutasteride and Bicalutamide but feels devastated due to increased sensitivity to DHT. She considers wigs, Minoxidil, and seeks advice on options like spironolactone, hair transplants, and therapy.
The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.
A person is microdosing estrogen for hair loss after finasteride and dutasteride failed, risking feminizing effects. Alternatives like minoxidil, RU58841, or hair transplants are suggested.
The user experienced side effects from spironolactone and is seeking alternatives for androgenetic alopecia (AGA), considering saw palmetto but unsure of its effectiveness. They are also exploring the possibility of using topical spironolactone, despite availability challenges.
A 35-year-old male is experiencing hair loss due to AGA and stress, using Minoxidil and finasteride for treatment. Users suggest waiting longer for results, considering additional treatments like microneedling, and consulting a dermatologist for scalp issues.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.